Rankia México Rankia Argentina Rankia Brasil Rankia Chile Rankia Colombia Rankia Czechia Rankia Deutschland Rankia España Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
16,363 / 16,979
#130898

Re: Farmas USA

SP
Gab cerrado y como dije si sólo se quedara en eso,,,,,,,
Al final verde por los pelos gracias a AMRN.

Volviendo al original que haría mucha más pupa. A ver si no se da.
#130899

Re: Farmas USA


AMGN semanal
se acerca a mi target ... 19x-200.

si alguien conoce algo que deba saber sobre porque esta teniendo esta corrección que hable ahora o calle para siempre .... ;)

#130900

Re: Farmas USA

Ivermectina, copio un post que he puesto en IV contestando a uno de estos que solo pone información falsa. Aparte de algún enlace sobre algunas de las cosas que mienten, al final resumen del fraude de los estudios que decían que la ivermectina funcionaba.

Ivermectin, hydroxychloroquine, "natural immunity", exaggerated heart damage from vaccines, false claims about risks to pregnant women and fertility, covid does not affect kids... have caused thousands of deaths, hospitalizations and suffering.
 
Everyone involved in spreading misinformation is guilty. I don't know how some people can sleep at night after what they've done.
 
Regarding ivermectin:
 
 
As background we have publicly bolt-gunned a number of studies of ivermectin. I don't mean niggled, I mean put down, here's a selection of the most important:
 
- Elgazzar
- Carvallo
- Cadegiani
- Samaha
- Niaee
 
Elgazzar: Contained fake data. Extreme terminal digit biases, duplicated patients, deaths in repeating patterns, deaths in control arm before study began
 
 
 
 
Carvallo: Contained unexplainable inconsistencies in between registry and paper. One of their recruitment centres states never participated. Statistician blamed for errors was not actually involved. Won't show data to own coauthors:
 
 
Cadegiani et al: contains impossible dependencies between consecutive patients (eg if one patient was physically active the next was 11 TIMES less likely to be), across multiple variables, no author could provide any explanation:
 
 
Samaha and Raad's dataset is trivially fake, and composed of blocks of 11 patients repeating in one arm and 17 patients repeating in the other. Even many of the authors on the paper accept it is fake and are arranging retraction.
 
 
The Niaee dataset claims to be randomised but includes extreme mismatches between arms at baseline. The chances of these range from thousands to one against to hundreds of quadrillions to one against:
 
 
 
This isn't the limit of the issues we have found. Some other studies have clear impossibilities but are still awaiting responses from authors etc.
#130901

Re: Farmas USA

OCUL

Un par de hilos interesantes:

https://twitter.com/sentivcapital/status/1447684337500098561

AC/DE (expanding on ct tweet)

Was concerned about AC PDUFA, which wasn't a sure win. If CRL, could have had -ve implications for DE trials, in terms of FDA support.

Now, the script is completely flipped. FDA clearly sees benefit of OCUL punctal platform imo.

With AC approval, $OCUL sales reps can get into doctors' offices and no longer have to worry about OR/ASC protocols

While Dex approval is for AC, reality is docs will use this for any inflamm where a short term steroid will be useful: patient convenience will be the big driver

If mgmt can get reimb back to where it was (which is expected?), procedure fee can be another big driver

Increases off-label use, for eg: the indication that OTX-DED is targeting, but if comorbid AC  (which is common) then used on-label

Likely turbo-boost for Dex 2022 sales

Implication for OTX-CSI (different active ingredient) more about FDA support for P3.

CSI works, plug works, CSI+plug should be easy win (hence quick enrollment despite upsize, +ve doc feedback)
Note: P2 trial not powered for stat sig, only n =40 per arm, look to see +ve trends

What AC approval signals: FDA prolly allows OCUL to design P3 immediately and perhaps the way mgmt wants to design:  vs fast degrader control

What to look for in CSI results (coming soon): +ve trends AND decision to move into P3 trials, if with near-term timing, even better

Finally, OTX-TKI in wAMD:

$EYPT has a binary readout on EYPT1901 at AAO Nov 13. Have changed view on this readout (will get into separately) and now lean +ve (disc: re-long)

If +ve, this validates $OCUL OTX-TKI (updated Aus data as poster at AAO), with US data incoming Feb '22

Summary:
  • Most risky catalyst (AC PDUFA) done and +ve -> boosts near term off-label & on-label Dex sales
  • OTX-CSI low hanging fruit -> likely P2 win + P3 near-term start
  • OTX-TKI likely validated by EYPT1901 data, with updated Aus data at AAO, US data Feb '22
-

https://twitter.com/buysidebio/status/1447616354253672455

importance of this for $OCUL:

1) establish reimbursement in the office setting 2 years before dry eye approval & allows Dextenza to move to office

2) AC approval builds confidence in rest of pipeline & CSI approval path given AC efficacy wasn’t great

3) off-label dry eye usage

If a patient with Allergic Conjunctivitis shows up with comorbidity of dry eye  it isn’t off label. AC sales could be bigger than expected if $OCUL positions AC this way. Can bundle with Dex and discount incentivizing docs more on top of procedure code pay

-You mean bundle Dex and CSI? Dex label specifies lower punctum, and even if it didn't I'm not sure occluding both puncta in an eye is feasible.

I meant selling both products to the same doctor. Strategy that works really well with competitors like Eypt. The classic Allergan Botox model. It becomes so much harder for competitors to compete given the amount of money the docs make on the various products.

https://twitter.com/jeromeleonard5/status/1447611389091237890

Actualizo con su última presentación:

https://ocutx.gcs-web.com/static-files/a7639a49-f84c-4de9-96a2-dbd5138d7a58

Y el mercado global de las indicaciones:

#130902

Re: Farmas USA

CVAC 

No sigue con la primera generación (que era inaprovable como comenté) y el contrato con EU queda cancelado. Era muy obvio y cuestión de tiempo. Espero que con todas las advertencias que he ido haciendo por aquí nadie estuviera.

https://twitter.com/MSollender/status/1447881776181899265?t=bh05MgVoxgxMWc6R6fDZcQ&s=19

-15% en PM, ya en $36. En realidad vale incluso bastante menos, dependerá de cómo suelten las manos fuertes que estaban cargados.
#130903

Re: Farmas USA

AMRN

peleando la MM50 diaria ... yo aqui soltaba lastre pero Nachete no me deja ... >_<



Pero el dedo gana, fuera 5,21 desde 4,95 y con eso termino el dia por hoy, creo ... porque estoy mirando de reojo a las NVAX pero no me hacen tilin nada nada, para que forzar, paso hasta que mejore algo el asunto
#130904

Re: Farmas USA

🤣🤣🤣
Enhorabuena,,,,,
Brokers destacados